Learning more about tukysa use in the Korean market
Part of Cancer, Skin clinical trials.
This study is collecting information from people in Korea who are already taking Tukysa for their condition. It helps researchers learn more about how the medicine works in real life, so they can better support patients and doctors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are currently being treated with Tukysa for an approved use, exactly as your doctor prescribes it.
- This is your first time using Tukysa.
- You are 18 years old or older.
- You are willing to sign a consent form confirming you understand the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at real-world data from people with HER2-positive metastatic breast cancer in Kazakhstan to understand how anti-HER2 treatments (other than trastuzumab deruxtecan) are used and how well they work. If you were diagnosed between 2022 and 2023, this research may help improve future care.
This trial tests a new drug called TQB2102 against a standard treatment (Kadcyla) for people with HER2-positive breast cancer that has spread or cannot be removed. It is for those whose cancer has worsened after previous HER2-targeted therapy.
This study follows patients in South Korea who have already received Kymriah (tisagenlecleucel) in a real-world setting. It aims to monitor their long-term health and any side effects over time.
This study watches how well a three-drug combination (tucatinib, capecitabine, and trastuzumab) works for women with breast cancer that has spread to other parts of the body and has a protein called HER2. You'll be treated as you normally would be in a clinic, and researchers will track how you respond.
This trial tests a new drug, TYK-00540, for people with solid tumors that have not responded to or cannot tolerate standard treatments. It also looks at specific types of breast and ovarian cancer.
This trial tests whether switching between two targeted therapy combinations can help women with HER2-positive advanced breast cancer that has progressed after previous treatments. It aims to find a new effective option for people who have already tried one or two lines of therapy.
Hear when a new Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.